100 % Datengenauigkeit
Wissenschaftlicher Support rund um die Uhr
0 % Toleranz bei der Produktqualität
Lagerstandorte
- New Jersey, USA
- Czech Republic, EU
- Mumbai, India
* Vorbehaltlich Verfügbarkeit
Dokumentation
Enthält: HPLC, MASS/LC-MS, 1H-NMR, FT-IR, Gehalt, Structure Elucidation Report (SER) sowie zusätzliche analytische Daten je nach Produkt.
Suxibuzone-D9
● Auf Lager
| Katalog-Nr.:: | DVE002132 |
|---|---|
| CAS-Nr.:: | N/A |
| Summenformel:: | C24H17D9N2O6 |
| Molare Masse:: | 447.53 g/mol |
Zusätzliche Informationen zu
Parent drug
SuxibuzoneIUPAC-Name
Butanedioic Acid 1-[(4-Butyl-3,5-dioxo-1,2-diphenyl-4-pyrazolidinyl)methyl] Ester-d9Pharmacopeial Synonyms
N/ASynonyme
N/ASMILES
O=C(N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3)C1(COC(CCC(O)=O)=O)C([2H])(C([2H])(C([2H])(C([2H])([2H])[2H])[2H])[2H])[2H]InChI
InChI=1S/C24H26N2O6/c1-2-3-16-24(17-32-21(29)15-14-20(27)28)22(30)25(18-10-6-4-7-11-18)26(23(24)31)19-12-8-5-9-13-19/h4-13H,2-3,14-17H2,1H3,(H,27,28)/i1D3,2D2,3D2,16D2Beschreibung
Suxibuzone-D9 is a deuterium-labeled impurity encountered in suxibuzone manufacturing that requires specific monitoring within the impurity profile. It is characterized as an isotopologue and identified by HPLC-UV with orthogonal confirmation by LC-MS to verify deuterium incorporation and by proton-decoupled NMR for structural assignment. Formation can occur from incomplete isotopic exchange or side reactions during synthesis and may affect assay accuracy and stability data if uncontrolled. A robust control strategy includes a qualified analytical standard, validated stability-indicating methods, forced-degradation studies and specification limits established in accordance with ICH Q3A/B to maintain drug substance quality and regulatory readiness.Angebot anfordern
„*“ zeigt erforderliche Felder an
Other products related to Suxibuzone impurities
Verunreinigungsstruktur
Name der Muttersubstanz
CAS-Nr.:
Name der Verunreinigung
Katalog-Nr.:
Suxibuzone
CAS No. 27470-51-5
Cat No. VE0027596
